Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.39 |
| ▸ | HTR2C | P28335 | 5/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CEL | P19835 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21115181 | 0.82 | SLC6A2 (0.35) | HTR2AHTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8963028 | 0.81 | HTR2A (0.34) | HTR2AHTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9300289 | 0.81 | HTR2A (0.34) | HTR2AHTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12739701 | 0.80 | CYP2C9 (0.35) | HTR2AHTR2C | |
| SCHEMBL12739694 | 0.79 | OPRL1 (0.34) | HTR2AHTR2C | |
| SCHEMBL10302154 | 0.78 | OPRL1 (0.33) | HTR2AHTR2CMAOBMAOA | |
| SCHEMBL10586080 | 0.78 | CEL (0.43) | CELDAO | |
| SCHEMBL10708166 | 0.78 | S1PR1 (0.41) | HTR2AHTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10708160 | 0.78 | S1PR1 (0.41) | HTR2AHTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7762384 | 0.77 | S1PR1 (0.41) | HTR2AHTR2CSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3502099-B1 | CYCLIC COMPOUND ACTING AS PDE4 INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-20190210975-A1 | CYCLIC COMPOUND ACTING AS PDE4 INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2019-07-11 | — | — | US | disclosed |
| EP-3502099-A1 | CYCLIC COMPOUND ACTING AS PDE4 INHIBITOR | Medshine Discovery Inc. (CN) | 2019-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210975-A1 | CYCLIC COMPOUND ACTING AS PDE4 INHIBITOR | PDE4A, PDE4B, PDE5A | HTR2A 3711/4885HTR2C 3518/4885SLC6A2 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.